Nature Metabolism: Alcohol addiction and liver damage are driven by endogenous fructose metabolism
A new paper in Nature Metabolism offered huge validation to the emerging theory that “fructose is the primary driver of metabolic syndrome”. The Paper: Identification of a common ketohexokinase-dependent link driving alcohol intake and alcohol-associated liver disease in mice TL;DR We usually think of alcohol and sugar as separate, but we’ve also had decades of […]
Antioxidants, Vol. 14, Pages 1490: Antidiabetic Agents as Antioxidant and Anti-Inflammatory Therapies in Neurological and Cardiovascular Diseases
Antioxidants, Vol. 14, Pages 1490: Antidiabetic Agents as Antioxidant and Anti-Inflammatory Therapies in Neurological and Cardiovascular Diseases Antioxidants doi: 10.3390/antiox14121490 Authors: Snehal Raut Luca Cucullo Neurological disorders and cardiovascular disease (CVD) remain leading causes of global morbidity and mortality and often coexist, in part through shared mechanisms of chronic inflammation and oxidative stress. Neuroinflammatory signaling, […]
Oh no, Ozempic! Eli Lilly’s New Weight-Loss Drug KOs Rival Treatments
How do you swear in Danish? Our AI chatbots are much too polite to help us out here, but we suspect you would have heard them all echoing outside the offices of Novo Nordisk yesterday. Eli Lilly, its leading rival in the burgeoning weight-loss drug market, announced trial results for an experimental obesity drug that […]
GLP-1 Drugs Tirzepatide and Semaglutide Provide Protection for Heart Health
submitted by /u/MassGen-Research [link] [comments]
Zealand Pharma, OTR, in $2.5B small-molecule metabolic deal
The quest for metabolic disease assets continues with another player promising top dollar for novel therapeutics that deliver. Copenhagen, Denmark-based Zealand Pharma A/S entered a collaboration and license agreement with newly formed OTR Therapeutics to pursue next-generation small-molecule therapeutics, beyond the Danish firm’s current peptide pipeline candidates focused on the GLP-1, GLP-2, GIP, amylin and […]
GLP-1 Drugs Linked to Lower Epilepsy Risk in Diabetes Patients
(MedPage Today) — GLP-1 receptor agonists were tied to a lower risk of developing epilepsy in adults with type 2 diabetes, a large U.S. study showed. Compared with DPP-4 inhibitors, GLP-1 receptor agonist use was associated with a 16% lower risk…
Should everybody be taking Ozempic? | Front Burner
We examine the rise and risks of blockbuster drugs like Ozempic, after the WHO conditionally recommended GLP-1 medications for the long-term treatment of obesity. »»» Subscribe to CBC News to watch more videos: http://bit.ly/1RreYWS For breaking news, video, audio and in-depth coverage: https://www.cbc.ca/news Follow CBC News on TikTok: https://www.tiktok.com/@cbcnews Subscribe to CBC News on Snapchat: […]
The potential of GLP-1 drugs to transform medicine exploded in 2025
We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight loss, but the extent of that potential really came to light in 2025
Eli Lilly drug candidate trial sees major weight loss, knee pain relief
In a phase 3 trial, Eli Lilly’s experimental drug retatrutide delivered an average 28.7% weight loss and reduced pain among adults with obesity or overweight and knee osteoarthritis. The trial recruited 445 participants and divided them equally to receive retatrutide 9 milligrams, retatrutide 12 milligrams or a placebo for 68 weeks, according to a Dec. […]
Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge?
Eli Lilly and Company LLY is one of the two companies that dominate the booming cardiometabolic space, driven by its successful GLP-1 therapies — Mounjaro for diabetes and Zepbound for weight loss, both comprising the same ingredient, tirzepatide, a dual GIP/GLP-1 RA. Despite facing strong competition from Novo Nordisk’s NVO semaglutide medicines, Ozempic for diabetes and Wegovy […]